Ondra Health Review
Best for: Cost-sensitive patients who want the lowest compounded-GLP-1 monthly cost and are willing to commit quarterly.
Ondra Health (ondra.health) is a 50-state compounded-GLP-1 telehealth platform operated by Ondra Health Inc. offering compounded semaglutide ($149/mo monthly or $279 quarterly = $93/mo) and compounded tirzepatide ($219/mo monthly or $499 quarterly ≈ $166/mo) on a 'same price all doses' model. The platform is GLP-1-only (no brand-name Wegovy/Zepbound, no peptide add-ons advertised). Live-verified 2026-05-15: LegitScript seal and HIPAA-compliant claim displayed; named provider network includes Dr. David Wasef, Dr. Ozita Cooper, Dr. Michael Wasef, Dr. James Teet, and Dr. Frank Suppa. Named 503A pharmacy partners: Hallandale Pharmacy, Quaker Community Pharmacy / New Life RX, Strive Pharmacy, VialsRX, and The Pharmacy Hub (Hallandale specifically unavailable in CA, KS, AR, MI, MN, AL, HI, MS, MA). Note: Wasef physicians overlap with Vytora Health's provider corporation (Wasef Health, PC) — possible shared-PC operating pattern but not flagged as identity-clone (no verbatim NPI+pharmacy match documented). WLR clinical-network disclosure (2026-05-15): clinical prescribing services are contracted to Wasef Health, PC (Pinellas Park, FL; Director Michael Wasef, MD), a multi-platform telehealth physician group that also prescribes for Cora Health, Refills Health, and sermorelin.com. Pharmacy partners and corporate operator are distinct from those other brands.
High confidence · Last verified 2026-05-15 via manual · How we verify provider data
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
The Bottom Line
Ondra Health is a solid telehealth option with balanced features and pricing.
Score Breakdown
Drugs Offered
Ondra Health prescribes the following GLP-1 medications. Tap a drug to read our clinical guide with FDA label info, dosing schedules, side effects, and trial data.
Pricing
| Dose | Form | Price/mo |
|---|---|---|
| All doses (monthly) | compounded | $149 |
| Quarterly ($279 billed = ~$93/mo) | compounded | $93 |
| All doses (monthly) | compounded | $219 |
| Quarterly ($499 billed = ~$166/mo) | compounded | $166 |
✓ Pros
- •Aggressive quarterly pricing — $93/mo effective for semaglutide is among the lowest in the segment
- •Named provider physicians (5 listed) — more transparency than typical compounded-GLP-1 platform
- •Five named 503A pharmacy partners disclosed
- •LegitScript seal + HIPAA claim displayed
- •Licensed in all 50 states
✗ Cons
- •No brand-name GLP-1 option (Wegovy/Zepbound/Mounjaro not offered)
- •Corporate physical address not disclosed
- •Hallandale pharmacy excluded in 9 states (CA, KS, AR, MI, MN, AL, HI, MS, MA) — fulfillment routing may vary
- •No medical director named
- •LegitScript certification number not displayed on visible pages
Ready to start with Ondra Health?
Starting at $93/month. See current pricing and start your free consultation.
Sources & methodology
Our Ondra Health review applies the same 6-dimension scoring framework we use for every provider. Pricing, FDA approval status, compounding rules, and clinical-trial efficacy claims are sourced from the primary regulatory and peer-reviewed literature below.
Sources & methodology — as of May 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.PCAB — Pharmacy Compounding Accreditation Board Standards— Accreditation Commission for Health Care (ACHC) / PCAB.
- 5.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 8.FDA — Ozempic (semaglutide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 9.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 10.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 11.FDA — Mounjaro (tirzepatide) Prescribing Information via Drugs@FDA— U.S. Food & Drug Administration.
- 12.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
Alternatives to Ondra Health
Editorial score · methodology
Editorial score · methodology
Editorial score · methodology
Frequently Asked Questions
Glossary references
Key terms in this article, linked to their canonical definitions.
- Semaglutide · Drugs and brands
- Tirzepatide · Drugs and brands
- Compounded GLP-1 · Pharmacy and drug forms
- 503A pharmacy · Pharmacy and drug forms
- PCAB accreditation · Pharmacy and drug forms
- Prior authorization (PA) · Insurance and regulatory
- Off-label use · Insurance and regulatory
- FDA Drug Shortage List · Insurance and regulatory
Ready to start with Ondra Health?
Starting at $93/month. See current pricing and start your free consultation.